Plasma concentrations of o,p′DDD, o,p′DDA, and o,p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T multicenter study

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages 1844-1851

  Hermsen, Ilse G ^a   Fassnacht, Martin ^b   Terzolo, Massimo ^c   Houterman, Saskia ^a   Den Hartigh, Jan ^d   Leboulleux, Sophie ^e   Daffara, Fulvia ^c   Berruti, Alfredo ^c   Chadarevian, Rita ^f   Schlumberger, Martin ^e   Allolio, Bruno ^b   Haak, Harm R ^a   Baudin, Eric ^e  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF TURIN   (Italy)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Laboratoire HRA Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 (2,4' DICHLORODIPHENYL) 2,2 DICHLOROETHENE; 1,1 (2,4' DICHLORODIPHENYL)ACETIC ACID; CISPLATIN; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; MITOTANE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TREATMENT RESPONSE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOTANE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 79956306619     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2676     Document Type: Article

References (36)

1. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P 1996 The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119:161-170
2. Schulick RD, Brennan MF 1999 Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6:719-726 (Pubitemid 30013647)
3. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE 2010 Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol 17:263-270
4. Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C 1992 Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112:972-979; discussion 979-980
5. Wooten MD, King DK 1993 Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72:3145-3155
6. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 25:891-897 (Pubitemid 32666390)
7. Assié G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M, Baudin E 2007 Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92: 148-154 (Pubitemid 46067523)
8. Allolio B, Hahner S, Weismann D, Fassnacht M 2004 Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60:273-287 (Pubitemid 38297116)
9. Nelson AA, Woodard G 1948 Adrenal cortical atrophy and liver damage produced in dogs by feeding 2,2-bis-(parachloro-phenyl)- 1,1-dichloroethane. Fed Proc 7:277
10. Bergenstal DM, Hertz R, Lipsett MB, Moy RH 1960 Chemotherapy of adrenocortical cancer with o,p′-DDD. Ann Intern Med 53:672
11. Cueto C, Brown JH, Richardson Jr AP 1958 Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology 62:334-339
12. Martz F, Straw JA 1980 Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o, p,′-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Drug Metab Dispos 8:127-130
13. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM 1994 Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947-951 (Pubitemid 24140681)
14. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED 2000 Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88:1159-1165
15. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M 2001 Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92: 1385-1392 (Pubitemid 32947821)
16. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A 2007 Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356: 2372-2380 (Pubitemid 46883771)
17. Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, Allolio B, Terzolo M 2010 Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 28:e401-e402; author reply e403
18. Huang H, Fojo T 2008 Adjuvant mitotane for adrenocortical cancer-a recurring controversy. J Clin Endocrinol Metab 93:3730-3732
19. Bodie B, Novick AC, Pontes JE, Straffon RA, Montie JE, Babiak T, Sheeler L, Schumacher P 1989 The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 141:257-260 (Pubitemid 19061293)
20. Seki M, Nomura K, Hirohara D, Kanazawa M, Sawada T, Takasaki K, Demura H 1999 Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. Endocr Relat Cancer 6:529-533 (Pubitemid 30048462)
21. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D 1984 The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47-53 (Pubitemid 14224356)
22. Cai W, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL 1995 Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 84:134-138
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
24. Hermsen IG, den Hartigh HJ, Haak HR 2010 Mitotane serum level analysis; good agreement between two different assays. Clin Endocrinol (Oxf) 73:271-272
25. Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T 2002 A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94:2333-2343 (Pubitemid 34457113)
26. Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL, Fojo AT 1991 Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 73:18-29 (Pubitemid 21901094)
27. Baudin E, Docao C, Gicquel C, Vassal G, Bachelot A, Penfornis A, Schlumberger M 2002 Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Ann Oncol 13:1806-1809 (Pubitemid 35439462)
28. Wängberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Odén, A, Ahlman H 2010 The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 17:265-272
29. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E 2010 Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17:797-807
30. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA 1989 Adrenal cortical carcinoma. Cancer 64:765-769 (Pubitemid 19185233)
31. Hutter Jr AM, Kayhoe DE 1966 Adrenal cortical carcinoma. Results of treatment with o,p′DDD in 138 patients. Am J Med 41:581-592
32. Lubitz JA, Freeman L, Okun R 1973 Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223:1109-1112
33. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J 2006 Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650-2655 (Pubitemid 44024632)
34. Cai W, Benitez R, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL 1995 Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p′- DDD] and its p,p′- and m,p′-isomers. Biochem Pharmacol 49:1483-1489
35. Kasperlik-Zaluska AA, Cichocki A 2005 Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. J Exp Ther Oncol 5:125-132 (Pubitemid 41739372)
36. Watson AD, Rijnberk A, Moolenaar AJ 1987 Systemic availability of o,p′-DDD in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism. Res Vet Sci 43:160-165 (Pubitemid 17142824)